MOLECULAR ANALYSIS OF GENOMIC ABNORMALITIES IN HUMAN GLIOMAS

被引:39
作者
BELLO, MJ
DECAMPOS, JM
KUSAK, ME
VAQUERO, L
SARASA, JL
PESTANA, A
REY, JA
机构
[1] CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN
[2] UNIV AUTONOMA MADRID, FAC MED, DEPT BIOCHEM, MADRID, SPAIN
[3] FDN JIMENEZ DIAZ, DEPT NEUROSURG, E-28040 MADRID, SPAIN
[4] FDN JIMENEZ DIAZ, DEPT PATHOL, E-28040 MADRID, SPAIN
[5] HOSP PRINCESA, DEPT NEUROSURG, MADRID, SPAIN
[6] CLIN PUERTA DE HIERRO, DEPT NEUROSURG, MADRID, SPAIN
关键词
D O I
10.1016/0165-4608(94)90195-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A series of 57 malignant gliomas, including 27 astrocytomas grade III-IV (glioblastoma multiforme), 15 astrocytomas grade I-II, and 15 tumors with major oligodendroglial component, was examined to detect molecular abnormalities of loci at specific chromosome regions. At the cytogenetic level, these regions have been shown to be nonrandomly involved in neoplastic development of these histologic subtypes of tumor. We used a panel of 24 polymorphic DNA probes to analyze loss of heterozygosity (LOH) at loci on chromosomes 7, 9, 10, 13, 17p, and 22q. In addition, the retinoblastoma (RB1) oncosuppressor gene, the platelet-derived growth factor A (PDGFA) gene, and the epidermal growth factor receptor (EGFR) gene were analyzed directly. Loss of genetic information on the short arm of chromosome 17 was observed in both low- and high-grade astrocytomas, whereas no oligodendroglial tumor was characterized by this type of aberration. LOH for chromosome 10, mainly compatible with loss of the entire chromosome, was primarily evidenced in the more malignant forms and in isolated cases diagnosed as low-grade astrocytomas. Again, no oligodendroglial tumor displayed losses of chromosome 10. In contrast, four tumors with major oligodendroglial component showed losses involving 9p markers, primarily interferon A and B (IFNA, IFNB); this feature was also observed in two low-grade astrocytomas and in 11 high-grade tumors. Isolated cases displayed LOH for markers on chromosomes 13 and 22, whereas EGFR amplification was almost exclusively evidenced in the more malignant forms which, in most instances, also presented LOH for chromosome 10. In general, the samples with lower malignancy stage displayed a lesser grade of abnormalities, mainly restricted to losses at 17p and chromosome 10 in astrocytomas grade I-II and at 9p in oligodendrogliomas. In contrast, about 50% of the high-grade tumor samples analyzed included abnormalities at two or more loci, with a recurrent association of EGFR amplification and LOH for chromosome 10; this association was evident in 26% of the high-grade astrocytomas.
引用
收藏
页码:122 / 129
页数:8
相关论文
共 44 条
  • [1] BELLO MJ, 1991, CANCER GENET CYTOGEN, V52, P252
  • [2] BIEGEL JA, 1992, CANCER RES, V52, P3391
  • [3] Cytogenetics and Molecular Genetics of Malignant Gliomas and Medulloblastoma
    Bigner, Sandra H.
    Vogelstein, Bert
    [J]. BRAIN PATHOLOGY, 1990, 1 (01) : 12 - 18
  • [4] BIGNER SH, 1988, CANCER RES, V48, P405
  • [5] EVIDENCE FOR A NEW TUMOR SUPPRESSOR LOCUS (DBM) IN HUMAN B-CELL NEOPLASIA TELOMERIC TO THE RETINOBLASTOMA GENE
    BROWN, AG
    ROSS, FM
    DUNNE, EM
    STEEL, CM
    WEIRTHOMPSON, EM
    [J]. NATURE GENETICS, 1993, 3 (01) : 67 - 72
  • [6] FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266
  • [7] FRANKEL RH, 1992, CANCER RES, V52, P1427
  • [8] FULTS D, 1989, CANCER RES, V49, P6572
  • [9] FULTS D, 1992, CANCER RES, V52, P674
  • [10] FULTS D, 1990, CANCER RES, V50, P5784